ClinicalTrials.gg
RecruitingNCT06892548Updated Aug 26, 2026

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

A Phase 1/2 interventional study of BNT324 and BNT327 in Advanced Lung Cancer, sponsored by BioNTech SE. Recruiting at 91 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.

Sponsored by BioNTech SE · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
594
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Planned enrollment
20th of 333
594 · median 63
Started
2025
with 59 others
Phase 1/2
42 of 365
30 open now
Primary completion
2028-09
later than 169 of 214 live
Registered
275th of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 20th largest by planned enrollment of the 333 interventional ones that give a count, is one of 60 that started in 2025, is one of 42 in phase 1/2, reaches primary completion later than 169 of the 214 other live ones, and was the 275th registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC).

Read the detailed description

This is a two-part study designed to evaluate and establish two safe combination dose levels (recommended Phase 2 dose [RP2D] and a lower/another combination dose level [RP2D-1]) of BNT324 with BNT327 (Part 1), to determine the optimal combination dose (dose optimization [DO]) in NSCLC and SCLC lead indication cohorts at the RP2D and RP2D-1, to evaluate the preliminary efficacy in selected lung cancer cohorts at the highest combination dose level (in a signal seeking Part 2), and to confirm the clinical efficacy of BNT324 in combination with BNT327 at the optimal dose level in participants with advanced lung cancer in expansion cohorts (proof-of-concept [POC] cohorts).

The study consists of a screening period, a treatment period, a safety follow-up period, and a long-term survival follow-up period.

In Part 1 participants with histologically or cytologically confirmed relapsed or progressive lung cancer (both SCLC and NSCLC are eligible) will receive BNT324 in combination with BNT327 using a dose escalation design.

In Part 2 of the study, BNT324 will be studied in combination with BNT327 at the RP2D compared to RP2D-1 in participants with advanced metastatic treatment-naïve NSCLC (DO Cohort 1) and relapsed/progressive SCLC after failure of cytotoxic chemotherapy with or without immuno-oncology (IO) (DO Cohort 2). The totality of the available data (e.g., safety, efficacy, pharmacokinetics etc.) will be reviewed to select the optimal dose. After the optimal dose is selected, additional participants in each cohort may be enrolled in the selected optimal dose.

In the signal seeking cohorts (Cohort 3-7), participants will receive BNT324 in combination with BNT327 at the RP2D from Part 1.

A predefined number of participants in Part 2 Cohort 1 and Cohort 2 will be randomized to one of the two dose levels (RP2D and RP2D-1) selected from Part 1 in a 1:1 ratio. Additional participants in Part 2 Cohort 1 and Cohort 2 may be enrolled in the selected optimal dose to further assess the efficacy and safety profile.

No randomization is planned for any other cohort in Part 2 or Part 1.

03

Conditions studied

  • Advanced Lung Cancer

Keywords

  • Small cell lung cancer (SCLC)
  • Non-small cell lung cancer (NSCLC)
  • Programmed death-ligand 1 (PD-L1)
  • Vascular endothelial growth factor (VEGF)
  • Bispecific antibody
  • BNT324 (DB-1311)
  • BNT327
  • Combination with chemotherapy
  • Combination with other investigational agents
  • Immunotherapy
  • Treatment-naïve
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years at the time of giving .
  • Histological or cytological confirmed unresectable advanced/ lung cancer. Histological classification may be based on tumor samples prior to metastatic disease. Participants with mixed histology must be classified based on the main component. Participants with NSCLC are eligible with any or no expression. Participants with AGA-positive disease must have received targeted therapy prior to enrollment in this study.

    • Part 1: Participants with NSCLC and SCLC
    • Part 2 Cohort 1: Participants with NSCLC (subpopulation 1) AGA negative, 1L
    • Part 2 Cohort 2: Participants with SCLC, 2L+
    • Part 2 Cohort 3: Participants with NSCLC (subpopulation 1) AGA negative, 2L+
    • Part 2 Cohort 4: Participants with NSCLC (subpopulation 2) AGA negative, 1L
    • Part 2 Cohort 5: Participants with NSCLC (subpopulation 2) AGA negative, 2L+
    • Part 2 Cohort 6: Participants with NSCLC AGA positive
    • Part 2 Cohort 7: Participants with SCLC, 1L
  • Have defined by version 1.1.
  • Have an performance status of 0 or 1.
  • Have a of ≥12 weeks.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with B7-H3 targeted therapy.
  • Prior treatment with ADC with topoisomerase inhibitor (e.g., datopotamab deruxtecan, trastuzumab deruxtecan). Note: This exclusion applies to participants in the /treatment-naïve cohorts in the advanced/ setting. Prior treatment with ADC with topoisomerase inhibitor payload is only allowed for participants in the second-line plus cohorts in the advanced/metastatic setting.
  • Is a candidate to locoregional treatment (including surgical resection, stereotactic radiotherapy or tumor ablation) with potential to induce complete or near complete response and prolonged tumor control (sometimes described as "radical" intent), per investigator's assessment.
  • Has a history of significant hematologic toxicity to prior lines of therapy, as assessed by investigator, e.g., Grade 4 febrile neutropenia or recurrent/persistent Grade 3 to 4 neutropenia.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply to all or some participants depending on the cohort.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
594 participants (estimated)

Study arms

  • Experimental
    Part 1 - BNT324 + BNT327 combination therapy

    Escalating combination dose levels of BNT324 and BNT327 to define RP2D and RP2D-1 for NSCLC and SCLC.

    Biological: BNT324 · Biological: BNT327

  • Experimental
    Part 2 - Cohort 1: RP2D of BNT324 + BNT327 and RP2D-1 of BNT324 + BNT327

    In subpopulation 1 of NSCLC actionable oncogenic alteration (AGA) negative, first-line (1L)

    Biological: BNT324 · Biological: BNT327

  • Experimental
    Part 2 - Cohort 2: RP2D of BNT324 + BNT327 and RP2D-1 of BNT324 + BNT327

    In SCLC, second-line plus (2L+)

    Biological: BNT324 · Biological: BNT327

  • Experimental
    Part 2 - Cohort 3: RP2D of BNT324 + BNT327

    In subpopulation 1 of NSCLC AGA negative, 2L+

    Biological: BNT324 · Biological: BNT327

  • Experimental
    Part 2 - Cohort 4: RP2D of BNT324 + BNT327

    In subpopulation 2 of NSCLC AGA negative, 1L

    Biological: BNT324 · Biological: BNT327

  • Experimental
    Part 2 - Cohort 5: RP2D of BNT324 + BNT327

    In subpopulation 2 of NSCLC AGA negative, 2L+

    Biological: BNT324 · Biological: BNT327

  • Experimental
    Part 2 - Cohort 6: RP2D of BNT324 + BNT327

    In NSCLC AGA positive

    Biological: BNT324 · Biological: BNT327

  • Experimental
    Part 2 - Cohort 7: RP2D of BNT324 + BNT327

    In SCLC, 1L

    Biological: BNT324 · Biological: BNT327

Interventions

  • BiologicalBNT324

    Intravenous infusion

    Also known as: DB-1311

  • BiologicalBNT327

    Intravenous infusion

06

What researchers measure

Primary outcomes

  1. Part 1 - Occurrence of dose limiting toxicities (DLTs) by dose level

    Time frame: During the DLT evaluation period, i.e., the time of initiation of the first dose of investigational medicinal product (IMP) up to 21 days]

  2. Part 1 - Occurrence of Treatment-emergent adverse events (TEAEs), serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by dose level

    Time frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first

  3. Part 1 - Occurrence of dose interruption, reduction, and treatment discontinuations due to TEAEs by dose level

    Time frame: From the time of the first dose of IMP to 90 days after the last dose of IMP or until new anticancer therapy is started, whichever occurs first

  4. Part 2 cohorts 1 and 2 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment arm

    Time frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first

  5. Part 2 cohorts 1 and 2 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment arm

    Time frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first

  6. Part 2 cohorts 1 and 2 - Objective response rate (ORR) by cohort and treatment arm

    ORR defined as the proportion of participants in whom a confirmed complete response (CR) or partial response (PR) is observed as best overall response (per response evaluation criteria in solid tumors \[RECIST\] version 1.1 based on the investigator's assessment).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

  7. Part 2 cohorts 3-7 - ORR by cohort

    ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per RECIST version 1.1 based on the investigator's assessment).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

Secondary outcomes

  1. Part 1 - ORR by dose level

    ORR, defined as the proportion of participants in whom a confirmed CR or PR is observed as best overall response (per RECIST version 1.1 based on the investigator's assessment).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

  2. Part 1 - Disease control rate (DCR) by dose level

    DCR, defined as the proportion of participants with confirmed CR, PR, or stable disease (SD) as best overall response (per RECIST version 1.1 based on the investigator's assessment).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

  3. Part 2 all cohorts - (PFS) by cohort and treatment arm

    PFS defined as the time from first dose of IMP to the first objective tumor progression (PD) or death from any cause, whichever occurs first, per RECIST version 1.1 based on the investigator's assessment.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

  4. Part 2 all cohorts - Duration of response (DOR) by cohort and treatment arm

    DOR, defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression (PD) or death from any cause, whichever occurs first (per RECIST version 1.1 based on the investigator's assessment).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

  5. Part 2 all cohorts - Overall survival (OS) by cohort and treatment arm

    OS, defined as the time from first dose of IMP to death from any cause.

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

  6. Part 2 all cohorts - DCR by cohort and treatment arm

    DCR, defined as the proportion of participants with confirmed CR, PR, or SD as best overall response (per RECIST version 1.1 based on the investigator's assessment).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

  7. Part 2 all cohorts - Time to response (TTR) by cohort and treatment arm

    TTR, defined as the time from first dose of IMP to first objective response (CR or PR per RECIST version 1.1 based on the investigator's assessment).

    Time frame: From the time of initiation of the first dose of IMP to end of study, i.e., up to 87 months

  8. Part 2 cohorts 3-7 - Occurrence of TEAEs, serious TEAEs, treatment-related TEAEs, and treatment-related serious TEAEs by cohort and treatment arm

    Time frame: From the time of the first dose of IMPs to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first

  9. Part 2 cohorts 3-7 - Occurrence of dose interruption, reduction, and treatment discontinuation due to TEAEs by cohort and treatment arm

    Time frame: From the time of the first dose of IMP to 90 days after the last IMP dose or until new anticancer therapy is started, whichever occurs first

07

Study locations

91 of 91 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2028, 40 months after the start.

Of 71 industry-sponsored phase 1/2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 74. This study's planned 40 months is below that.

Counting every sponsor, half of 98 studies reached it within 54 months; a quarter within 44 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2025
First posted
Mar 24, 2025
StartActual
May 2, 2025
Primary completionEst.
Sep 2028
CompletionEst.
May 2032
Last update
Aug 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06892548
Lead sponsor
BioNTech SE
Collaborators
DualityBio Inc.
Responsible party
Sponsor
First posted
Mar 24, 2025
Start date
May 2, 2025
Primary completion
Sep 2028 (estimated)
Completion
May 2032 (estimated)
Last update
Aug 26, 2026

Study contacts

BioNTech clinical trials patient information
Contact
patients@biontech.de
+49 6131 9084 ext. 0
BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elfetabart Drozuntecan · Pumitamig

Start the discussion